株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国のトラスツズマブ市場調査

Investigation Report on China Trastuzumab Market, 2010-2019

発行 China Research and Intelligence 商品コード 296113
出版日 ページ情報 英文 20 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。
Back to Top
中国のトラスツズマブ市場調査 Investigation Report on China Trastuzumab Market, 2010-2019
出版日: 2015年06月18日 ページ情報: 英文 20 Pages
概要

トラスツズマブ(Trastuzumab)はHER2/neu受容体を妨げるモノクロナール抗体であり、主として特定の乳癌の治療に用いられます。トラスツズマブはHER2陽性転移性乳癌の治療に大きな影響を持っています。中国では、医療環境の制限と知識不足によって、乳腺疾患検査を毎年受ける女性が10%以下です。そのため、初期段階で発見される乳癌は、米国では80%ですが、中国では僅か20%に留まっています。中国の病院市場においては、Shanghai Roche と GENENTECHがトラスツズマブのシェアを占めています。2005-2014年の間に、病院におけるトラスツズマブの市場規模はCAGR 52.9%を示しました。

当レポートでは、中国のトラスツズマブ市場について分析し、主要メーカーの市場シェア、中国の病院市場における価格変化・売上額、主要企業、および市場展望などを提供しております。

第1章 トラスツズマブ関連のコンセプト

  • 適応症
  • 世界市場における販売状況

第2章 中国におけるトラスツズマブの市場概要

  • 特許状況
  • 主要メーカー
  • 市場規模

第3章 中国におけるトラスツズマブの販売額調査

  • 売上額
    • 総売上額
    • 地域別
  • 売上高
    • 総売上高
    • 地域別

第4章 中国における主要トラスツズマブメーカーの市場シェア調査

  • 市場シェア:売上額別
  • 市場シェア:売上高別

第5章 トラスツズマブの市場規模調査:中国における投薬形態別

  • 市場シェア:売上額・投薬形態別
  • 市場シェア:売上高・投薬形態別

第6章 中国の病院市場におけるトラスツズマブの基準価格

  • GENENTECH (商標名: Herceptin)のトラスツズマブ製品
  • Shanghai Roche (商標名: Herceptin)のトラスツズマブ製品

第7章 中国における主要トラスツズマブメーカーの分析

  • Shanghai Roche Pharmaceuticals Ltd.
  • GENENTECH (米)

第8章 中国のトラスツズマブ市場の展望

  • 市場規模予測
  • 競合パターン予測

主要チャート

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 1506217

Monoclonal antibody, an epochal drug variety, plays an important role in the upgrading process of treatments for tumor and autoimmune disease, and has become a mainstream in the global market of targeting therapeutic agents. The manufacturers of antibody mainly concentrate in the hands of such drug giants as Roche, Amgen, Johnson & Johnson, Abbott, Novartis and Merck, among which Roche's Genetech boasts of the largest amount of monoclonal antibody varieties.

Developed by Genentech, trastuzumab was approved by FDA to be used in clinic in Sep. 1998 under the trade name of Herceptin, a major product of Roche. In 2013, the sales value of trastuzumab was USD 6.56 billion around the world.

After entering China in 2002 for the treatment of HER2 metastatic breast cancer, trastuzumab develops fast with annual sales value rising from less than CNY 20 million in 2005 to CNY 577 million in 2014 and CAGR during this period reaching up to 52.9%. Currently, trastuzumab in the Chinese market are monopolized by the subsidiary companies of Roche such as Genentech and Shanghai Roche Pharmaceutical Co., Ltd who has the largest market share of 80.60% with sales value in 2014 reaching up to CNY 465 million.

Due to its low toxicity and obvious therapeutic effects, trastuzumab can prolong patients' lives and improve the life quality of patients with advanced cancer, thus becoming the major driving force behind the growth of tumor monoclonal antibody market. The market size of trastuzumab in China is expected to keep expanding in the next few years.

Readers can get at least the following information from this report:

  • market size of trastuzumab in China
  • price of trastuzumab in Chinese market
  • major manufacturers of trastuzumab in Chinese market
  • market outlook of trastuzumab in China

The author suggests the following groups of people purchase this report:

  • manufacturers of monoclonal antibody
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Trastuzumab

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Trastuzumab in China

  • 2.1. Patent and Approval Status of Trastuzumab in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Trastuzumab in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Trastuzumab in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Trastuzumab in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Trastuzumab in Chinese Hospitals in 2014

  • 6.1. GENENTECH(US) (Trade Name: Herceptin)
  • 6.2. Shanghai Roche Pharmaceutical Co., Ltd (Trade Name: Herceptin)

7. Major Manufacturers of Trastuzumab in Chinese Market, 2010-2014

  • 7.1. Shanghai Roche Pharmaceutical Co., Ltd
  • 7.2. GENENTECH (US)

8. Market Outlook of Trastuzumab in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Sales Status of Trastuzumab in China
  • Chart Sales Value of Trastuzumab in China, 2010-2014
  • Chart Sales Value of Trastuzumab in Some Regions in China, 2010-2014
  • Chart Sales Volume of Trastuzumab in China, 2010-2014
  • Chart Sales Volume of Trastuzumab in Some Regions in China, 2010-2014
  • Chart Market Share of TOP2 Manufacturers of Trastuzumab for Sales Value in China, 2010-201
  • Chart Sales Value and Market Share of Trastuzumab Made by Shanghai Roche in China, 2010-2014
  • Chart Sales Value and Market Share of Trastuzumab Made by GENENTECH(US) in China, 2010-2014
  • Chart Sales Value and Market Share of Trastuzumab Injection in China, 2010-2014
  • Chart Sales Volume and Market Share of Trastuzumab Injection in China, 2010-2014
  • Chart Price of Trastuzumab Made by GENENTECH(US) in Some Chinese Cities in 2014
  • Chart Price of Trastuzumab Made by Shanghai Roche Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top